Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM93CTQ)

Drug Name

AR08 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor (ADR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Celiprolol hcl	DMD5LBX	Hypertension	BA00-BA04	Approved	[3]
Ovine corticotropin-releasing hormone	DME0F98	Cushing disease	5A70	Approved	[4]
Befunolol hci	DM8WCXM	Glaucoma/ocular hypertension	9C61	Approved	[3]
Oxilofrine	DMRKOS1	Orthostatic hypotension	BA21	Approved	[4]
Terbutyline	DMVPWLZ	Hypertension	BA00-BA04	Approved	[4]
Guanadrel Sulfate	DM6S157	Hypertension	BA00-BA04	Approved	[5]
Dabelotine	DMP2SGN	Cognitive impairment	6D71	Phase 3	[6]
PMID30124346-Compound-60TABLE5	DM3QX0R	Dyskinesia	MB47.4	Patented	[7]
Etilefrine	DM67PWD	Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[4]
AIR-Epinephrine	DMGAERX	Allergy	4A80-4A85	Discontinued in Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01876719) AR08 for Treatment of ADHD in Children. U.S. National Institutes of Health.
2	Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
3	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
7	5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
8	Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.